SCHEMBL206134

SCHEMBL206134

CCCCCCCCc1ccc(Nc2nc(-c3cccnc3)cs2)cc1C(F)(F)F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.56
KMT2A Q03164 12/20 0.56
RAB9A P51151 10/20 0.56
NPC1 O15118 8/20 0.56
CASP3 P42574 2/20 0.56
SENP8 Q96LD8 2/20 0.56
SENP7 Q9BQF6 2/20 0.56
SENP6 Q9GZR1 2/20 0.56
MAPT P10636 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
GAA P10253 3/20 0.53
MAPK1 P28482 2/20 0.52
KIT P10721 2/20 0.51
PKM P14618 2/20 0.51
LMNA P02545 1/20 0.51
VCP P55072 1/20 0.51
TP53 P04637 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A1 P04798 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128737 1.00 MEN1 (0.56) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL207920 0.90 RAB9A (0.53) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL3117347 0.90 MEN1 (0.55) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL3130365 0.89 MEN1 (0.61) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL209132 0.88 MEN1 (0.51) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL3120185 0.87 S1PR1 (0.43) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL3132703 0.86 MEN1 (0.55) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL206841 0.86 MEN1 (0.54) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL206853 0.86 MEN1 (0.56) MEN1KMT2ARAB9ANPC1CASP3
SCHEMBL206765 0.86 MEN1 (0.56) MEN1KMT2ARAB9ANPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US claimed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US claimed
US-8183263-B2 Heteroaryl substituted thiazoles ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-22 US disclosed
US-8183263-B2 Heteroaryl substituted thiazoles ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-22 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8106209-B2 Substituted aminothiazole prodrugs of compounds with anti-HCV activity ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-8106209-B2 Substituted aminothiazole prodrugs of compounds with anti-HCV activity ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
EP-2297143-A1 SUBSTITUTED AMINOTHIAZOLE PRODRUGS OF COMPOUNDS WITH ANTI-HCV ACTIVITY Achillion Pharmaceuticals, Inc. (US) 2011-03-23 EP disclosed
WO-2009149436-A1 SUBSTITUTED AMINOTHIAZOLE PRODRUGS OF COMPOUNDS WITH ANTI-HCV ACTIVITY ACHILLION PHARMACEUTICALS, INC. (US) 2009-12-10 WO disclosed
US-20090304605-A1 Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity ACHILLION PHARMACEUTICALS, INC. (US) 2009-12-10 US disclosed
US-20090304605-A1 Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity ACHILLION PHARMACEUTICALS, INC. (US) 2009-12-10 US disclosed
US-20090041720-A1 HETEROARYL SUBSTITUTED THIAZOLES ACHILLION PHARMACEUTICALS, INC. (US) 2009-02-12 US disclosed
US-20090041720-A1 HETEROARYL SUBSTITUTED THIAZOLES ACHILLION PHARMACEUTICALS, INC. (US) 2009-02-12 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 MEN1 3862/4885KMT2A 3476/4885RAB9A 1357/4885
US-20090304605-A1 Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity BCAT1, CCNT1, EIF2AK2 MEN1 4749/4885KMT2A 2806/4885RAB9A 948/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 MEN1 3862/4885KMT2A 3476/4885RAB9A 1357/4885
US-20090041720-A1 HETEROARYL SUBSTITUTED THIAZOLES CYP3A43, CYP3A7, HAVCR2 MEN1 2144/4885KMT2A 3706/4885RAB9A 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.